⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RVMD News
Revolution Medicines, Inc. Common Stock
ERAS ALERT: Securities Fraud Class Action Launched Against Erasca, Inc. - August 10, 2026 Deadline
accessnewswire.com
ERAS
RVMD
Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer
globenewswire.com
RVMD
Investors in Erasca, Inc. (ERAS): Protect Your Rights - Contact Levi & Korsinsky Before August 10, 2026
accessnewswire.com
ERAS
RVMD
Form 8-K
sec.gov
RVMDW
RVMD
Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.
globenewswire.com
RVMD
ERAS SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Erasca, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
accessnewswire.com
ERAS
RVMD
Levi & Korsinsky Urges Erasca, Inc. (ERAS) Shareholders to Act Before Lead Plaintiff Deadline August 10, 2026
accessnewswire.com
ERAS
RVMD
Investor Alert: Deadline Approaching to Join Erasca, Inc. (ERAS) Class Action - Contact Levi & Korsinsky
accessnewswire.com
ERAS
RVMD
ERAS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Erasca, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
accessnewswire.com
ERAS
RVMD
Lost Money on Erasca, Inc. (ERAS)? Contact Levi & Korsinsky Before August 10, 2026 to Join Class Action
accessnewswire.com
ERAS
RVMD